Treatment of peritoneal carcinomatosis from breast cancer by maximal cytoreduction and HIPEC: A preliminary report on 5 cases

Maurizio Cardi, Paolo Sammartino, Maria Luisa Framarino, Daniele Biacchi, Enrico Cortesi, Simone Sibio, Fabio Accarpio, Claudio Luciani, Antonella Palazzo, Angelo di Giorgio

Research output: Contribution to journalArticlepeer-review

Abstract

Although peritoneal carcinomatosis from breast cancer is a rare event it frequently causes morbidity and mortality. Current literature provides scarce information on its management. We report outcomes in 5 patients (mean age 59.4 years) with peritoneal carcinomatosis from breast cancer treated with maximal cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) by the closed technique, at 40°C for 1h with cisplatin 75mg/m2. The primary breast cancer was a ductal carcinoma in 3 patients and a lobular carcinoma in 2. Mean peritoneal cancer index was 20.2. In 4 of the 5 patients surgery achieved macroscopic complete cytoreduction. One patient died of disease at 56 months, 4 are alive and disease-free at 13, 45, 74 and 128 months. These encouraging outcomes suggest that cytoreduction and HIPEC is a promising approach to offer to highly selected patients with peritoneal carcinomatosis from breast cancer and that this approach merit investigation in a larger series.

Original languageEnglish
Pages (from-to)845-849
Number of pages5
JournalBreast
Volume22
Issue number5
DOIs
Publication statusPublished - Oct 2013

Keywords

  • Breast cancer
  • Cytoreduction
  • HIPEC
  • Peritoneal metastases

ASJC Scopus subject areas

  • Surgery

Fingerprint

Dive into the research topics of 'Treatment of peritoneal carcinomatosis from breast cancer by maximal cytoreduction and HIPEC: A preliminary report on 5 cases'. Together they form a unique fingerprint.

Cite this